PL2407537T3 - Humanizowane przeciwciało PcrV wykazujące aktywność przeciwko Pseudomonas - Google Patents

Humanizowane przeciwciało PcrV wykazujące aktywność przeciwko Pseudomonas

Info

Publication number
PL2407537T3
PL2407537T3 PL10750805T PL10750805T PL2407537T3 PL 2407537 T3 PL2407537 T3 PL 2407537T3 PL 10750805 T PL10750805 T PL 10750805T PL 10750805 T PL10750805 T PL 10750805T PL 2407537 T3 PL2407537 T3 PL 2407537T3
Authority
PL
Poland
Prior art keywords
pcrv antibody
humanized
pseudomonal activity
pseudomonal
activity
Prior art date
Application number
PL10750805T
Other languages
English (en)
Other versions
PL2407537T6 (pl
Inventor
Yoshinori Yamano
Yoshito Numata
Takafumi Sato
Toshinaga Tsuji
Keiko Kawamoto
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of PL2407537T3 publication Critical patent/PL2407537T3/pl
Publication of PL2407537T6 publication Critical patent/PL2407537T6/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL10750805T 2009-03-11 2010-03-09 Humanizowane przeciwciało PcrV wykazujące aktywność przeciwko Pseudomonas PL2407537T6 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009057929 2009-03-11
EP20100750805 EP2407537B3 (en) 2009-03-11 2010-03-09 Humanized pcrv antibody having anti-pseudomonal activity
PCT/JP2010/053828 WO2010104052A1 (ja) 2009-03-11 2010-03-09 抗緑膿菌作用を有するヒト化ＰｃｒＶ抗体

Publications (2)

Publication Number Publication Date
PL2407537T3 true PL2407537T3 (pl) 2015-04-30
PL2407537T6 PL2407537T6 (pl) 2016-07-29

Family

ID=42728341

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10750805T PL2407537T6 (pl) 2009-03-11 2010-03-09 Humanizowane przeciwciało PcrV wykazujące aktywność przeciwko Pseudomonas

Country Status (18)

Country Link
US (2) US20120093808A1 (pl)
EP (1) EP2407537B3 (pl)
JP (1) JP5780595B2 (pl)
KR (1) KR101686261B1 (pl)
CN (2) CN102341496B (pl)
AU (1) AU2010222150B2 (pl)
BR (1) BRPI1008977A2 (pl)
CA (1) CA2754900A1 (pl)
DK (1) DK2407537T6 (pl)
EA (1) EA021101B1 (pl)
ES (1) ES2529734T7 (pl)
IL (1) IL214959A (pl)
MX (1) MX2011009100A (pl)
PL (1) PL2407537T6 (pl)
PT (1) PT2407537E (pl)
SG (2) SG10201400520WA (pl)
TW (1) TWI489995B (pl)
WO (1) WO2010104052A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4766716B2 (ja) * 2008-01-10 2011-09-07 塩野義製薬株式会社 ＰｃｒＶに対する抗体
EA021101B1 (ru) 2009-03-11 2015-04-30 Шионоги Энд Ко., Лтд. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К PcrV, ОБЛАДАЮЩЕЕ АКТИВНОСТЬЮ ПРОТИВ ПСЕВДОМОНАС
SI2776065T1 (sl) * 2011-11-07 2020-10-30 Medimmune Limited Kombinacijske terapije z uporabo molekul, ki vežejo anti-Pseudomonas Psl in PcrV
JP6494519B6 (ja) * 2013-09-30 2019-07-31 第一三共株式会社 抗ｌｐｓ ｏ１１抗体
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
CN113966343A (zh) * 2019-06-11 2022-01-21 瑞泽恩制药公司 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
CN114072145B (zh) * 2020-06-01 2024-06-11 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途
CN118440191A (zh) * 2024-05-11 2024-08-06 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
DE69930166T2 (de) 1998-11-25 2006-12-14 MCW Research Foundation, Inc., Milwaukee Verfahren und zusammensetzungen für impfung mit dem pseudomonas aeruginosa v-antigen
US20030228324A1 (en) 1999-05-06 2003-12-11 Malcolm Andrew J. Peptide compositions and methods of producing and using same
EP1353688B1 (en) * 2001-01-26 2006-12-06 MCW Research Foundation, Inc. Method and compositions for immunization with the pseudomonas v antigen
KR20070007265A (ko) 2003-12-30 2007-01-15 쌘디스크 코포레이션 제어 데이터 관리를 구비한 비휘발성 메모리 및 방법
WO2005069970A2 (en) * 2004-01-20 2005-08-04 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
CN101454446A (zh) 2006-03-30 2009-06-10 明治制果株式会社 绿脓杆菌的外膜蛋白pa0427
US20100330100A1 (en) 2007-06-29 2010-12-30 Meiji Seika Kaisha Ltd. Pseudomonas aeruginosa-outer membrane protein pa4710
AU2008333985B2 (en) * 2007-11-30 2015-02-05 Kalobios Pharmaceuticals, Inc. Antibodies to the PcrV antigen of pseudomonas aeruginosa
JP4766716B2 (ja) * 2008-01-10 2011-09-07 塩野義製薬株式会社 ＰｃｒＶに対する抗体
EA021101B1 (ru) 2009-03-11 2015-04-30 Шионоги Энд Ко., Лтд. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К PcrV, ОБЛАДАЮЩЕЕ АКТИВНОСТЬЮ ПРОТИВ ПСЕВДОМОНАС

Also Published As

Publication number Publication date
US9085611B2 (en) 2015-07-21
PL2407537T6 (pl) 2016-07-29
CN104119437A (zh) 2014-10-29
EP2407537B3 (en) 2015-05-20
EA021101B1 (ru) 2015-04-30
PT2407537E (pt) 2015-02-17
DK2407537T3 (en) 2015-02-09
IL214959A (en) 2016-04-21
AU2010222150B2 (en) 2015-07-16
WO2010104052A1 (ja) 2010-09-16
IL214959A0 (en) 2011-11-30
DK2407537T6 (en) 2015-07-27
CN102341496A (zh) 2012-02-01
KR101686261B1 (ko) 2016-12-14
TWI489995B (zh) 2015-07-01
CN102341496B (zh) 2014-07-02
ES2529734T7 (es) 2015-08-11
TW201032825A (en) 2010-09-16
CA2754900A1 (en) 2010-09-16
KR20110128856A (ko) 2011-11-30
EP2407537B1 (en) 2014-11-26
MX2011009100A (es) 2011-09-27
JP5780595B2 (ja) 2015-09-16
ES2529734T3 (es) 2015-02-25
SG10201400520WA (en) 2014-05-29
EP2407537A4 (en) 2012-12-26
JPWO2010104052A1 (ja) 2012-09-13
SG174225A1 (en) 2011-10-28
EP2407537A1 (en) 2012-01-18
BRPI1008977A2 (pt) 2016-10-04
US20120093808A1 (en) 2012-04-19
AU2010222150A1 (en) 2011-09-08
US20130108627A1 (en) 2013-05-02
EA201190163A1 (ru) 2013-01-30

Similar Documents

Publication Publication Date Title
IL220404A (en) Antiseptic antibodies
ZA201005348B (en) Humanized anti-c5ar antibodies
ZA201106480B (en) Humanized anti-cd19 antibody formulations
IL217919A0 (en) Humanized anti-cdcp1 antibodies
SG10201401331TA (en) Anti-siglec-15 antibody
HK1168871A1 (zh) 單克隆抗體
ZA201202793B (en) Humanized antibodies against human il-22ra
IL214959A0 (en) Humanized pcrv antibody having anti-pseudomonal activity
IL214840A0 (en) Humanised antibodies with anti-tumour activity
PL2463368T3 (pl) Humanizowane przeciwciało anty-oligomer amyloidu B
EP2463369A4 (en) HUMANIZED ANTIBODIES AGAINST AMYLOID B OLIGOMERS
ZA201004770B (en) Improved humanized anti-human x9-integrin antibody
GB2473934B (en) Anti-VEEV antibody
GB0804687D0 (en) Humanized antibody
GB0804686D0 (en) Humanized antibody
GB0804684D0 (en) Humanized antibody
AU2009901129A0 (en) Humanised antibodies with anti-tumour activity
GB0911712D0 (en) Antibody